About Pharma Connect Navigator

Garden State Venture Partners, Rowan Innovation Venture Fund Portfolio →

For founder and CEO Nicholas Denzer, the mission behind Pharma Connect Navigator is personal.

At 19 years old, Nicholas was diagnosed with a rare skull-base tumor that required major treatment and surgery.

His recovery affected abilities most people rarely have to think about. He had to relearn how to walk, talk, eat, and chew.

The initial treatment was only the beginning. Over the following four years, Nicholas underwent eight reconstructive surgeries as part of a long recovery.

That experience changed the way he thought about healthcare and medical innovation.

Within the life-sciences industry, innovation may be discussed in terms of molecules, devices, manufacturing processes, clinical programs, regulatory pathways, or development milestones.

For a patient, the meaning is much more immediate.

It can represent another option, a better recovery, more time, or a different future.

Nicholas's medical experience did not make him a scientist, physician, regulatory professional, or CMC expert. What it gave him was a lasting appreciation for the enormous network of people, companies, technologies, and systems required to turn scientific innovation into something that can ultimately help a patient.

That became the motivation.

The specific problem Pharma Connect Navigator would solve came later.

While studying marketing and entrepreneurship at Rowan University, Nicholas became increasingly interested in the intersection of healthcare, biotechnology, technology, and entrepreneurship.

Rather than beginning with a predetermined product, he began with customer discovery.

Through the NSF I-Corps methodology and Rowan University's entrepreneurship ecosystem, Nicholas spoke directly with people involved in biotechnology development, CMC, pharmaceutical manufacturing, outsourcing, commercialization, and related areas.

Rowan University participates in the NSF I-Corps Northeast Region Hub, and its Propelus program emphasizes direct customer interviews, testing business hypotheses, understanding workflows, and identifying real market needs.

NSF I-Corps / Propelus at Rowan University →

Those conversations continued beyond the program.

Nicholas spoke with biotechnology founders, CMC professionals, consultants, CDMO teams, manufacturing professionals, business-development leaders, advisors, investors, and others involved in moving pharmaceutical programs toward clinical and commercial manufacturing.

A recurring issue began to emerge.

The industry did not necessarily have a shortage of manufacturing organizations.

The challenge was determining which manufacturing organizations actually fit a specific program.

Biotechnology and pharmaceutical companies can choose from a large and complex landscape of CDMOs, CMOs, and manufacturing facilities.

Those organizations differ across:

• modalities
• manufacturing technologies
• development stages
• production scales
• technical capabilities
• regulatory experience
• geographic locations
• support services
• facility configurations
• equipment
• project requirements

Finding companies is one problem.

Determining which of those companies and facilities are actually relevant to a particular manufacturing program is another.

For many teams, that process is still assembled through some combination of referrals, personal networks, conferences, Google searches, CDMO websites, PDFs, spreadsheets, directories, consultants, regulatory databases, LinkedIn, and direct outreach.

Each of those sources can be useful.

But the sponsor still has to connect the information.

A manufacturer may support the right modality but not the required scale.

A CDMO may advertise a capability that exists at only one of its facilities.

A company may appear attractive at the corporate level while important project-specific information remains unclear.

A facility may look technically suitable while raising regulatory questions that deserve further investigation.

And a manufacturer that is an excellent partner for one program may be poorly suited to another.

Traditional discovery tools can help answer:

“Which CDMOs exist?”

PCN was built to help answer a more specific question:

“Which CDMOs and facilities appear to fit the requirements of this manufacturing program?”

Pharma Connect Navigator starts with the manufacturing program rather than the company name.

Biotechnology, pharmaceutical, and CMC teams can define requirements relating to areas such as:

• modality
• development stage
• manufacturing services
• technical capabilities
• regulatory requirements
• manufacturing scale
• project timing
• budget
• geography
• support services
• facility requirements
• other project-specific considerations

PCN then evaluates structured information about CDMOs and manufacturing facilities against those requirements.

The objective is not to create a universal ranking of manufacturers.

There is no universally best CDMO.

The appropriate partner depends on the needs of the specific program.

PCN's sourcing process is organized around:

1. DEFINE→
2. QUALIFY→
3. PRIORITIZE→
4. MATCH→
5. COMPARE→
6. DILIGENCE→
7. CONNECT

Teams can move from defining a project toward identifying potential manufacturing partners, comparing relevant information, investigating open questions, and requesting an introduction when a CDMO appears worth engaging.

PCN supports sourcing and preliminary diligence.

It does not replace formal technical assessment, supplier qualification, quality audits, regulatory review, contracting, or professional CMC judgment.

How PCN Matches Biotech Programs With CDMOs →

CDMO selection is more complex than keyword matching.

A manufacturer should not appear highly relevant simply because its website mentions several terms that also appear in a sponsor's project description.

Some requirements can materially determine whether a manufacturing partner should remain under consideration.

Other factors are more useful for comparing otherwise viable candidates.

PCN's matching framework is therefore derived from the decision logic, established CMC practices, and industry-standard considerations used by experienced CMC professionals when evaluating and shortlisting CDMOs for biotechnology and pharmaceutical manufacturing programs.

The platform combines structured qualification logic, weighted project-fit criteria, customizable priorities, facility-level information, and relevant regulatory context.

PCN is designed to structure and accelerate repeatable sourcing work while leaving technical interpretation and professional judgment where they belong: with experienced people.

Matching Methodology →

CDMO sourcing does not stop at the company level.

A large manufacturing organization may operate numerous facilities, and those sites can differ significantly in their:

• manufacturing technologies
• equipment
• dosage forms
• production scales
• modalities
• development capabilities
• geographic location
• regulatory history

A company may truthfully state that it supports a particular manufacturing capability without every facility in its network performing that work.

For that reason, PCN incorporates facility-level information where available.

The goal is to move beyond:

“Does this company offer this capability?”

and toward:

“Which facility appears relevant to the requirements of this specific program?”

That distinction is an important part of PCN's approach to CDMO sourcing and manufacturing-partner evaluation.

Technical capability is only one part of evaluating a potential manufacturing partner.

PCN also incorporates publicly available regulatory information to help users identify questions that may deserve further investigation.

For relevant U.S. FDA information, PCN can associate manufacturing establishments with public FDA records using Facility Establishment Identifier, or FEI, numbers.

This can help connect the appropriate manufacturing facility with information such as:

• FDA inspection information
• Form FDA 483 observations
• Warning Letters
• other relevant publicly available FDA records

PCN does not treat a historical Form FDA 483 as an automatic reason to exclude a manufacturer.

A Form 483 is not, by itself, a final FDA determination of regulatory noncompliance.

Regulatory information requires context.

PCN's role is to make relevant information easier to investigate during the sourcing process so that sponsor teams can identify better questions before proceeding into deeper diligence.

FDA Form 483s and CDMO Selection →

Pharma Connect Navigator has been developed around a simple principle:

Build with the people who understand the problem firsthand.

Nicholas's academic and professional background is in entrepreneurship and marketing.

Rather than positioning himself as the technical expert in every area of pharmaceutical manufacturing, he has built PCN through continued engagement with people across the life-sciences ecosystem.

That has included biotechnology founders, CMC leaders, consultants, CDMO executives, pharmaceutical professionals, manufacturing teams, business-development leaders, technical experts, advisors, and investors.

That philosophy grew directly from the customer-discovery discipline Nicholas learned through NSF I-Corps:

Understand the workflow. Test the assumptions. Listen to the people doing the work. Build. Learn. Improve.

That process continues to shape PCN.

Pharma Connect Navigator began developing while Nicholas was a student at Rowan University's Rohrer College of Business and School of Innovation & Entrepreneurship.

Rowan's entrepreneurship ecosystem provided an environment where the company could repeatedly test its assumptions, positioning, business model, and product direction.

Through NSF I-Corps Propelus, PCN used structured customer discovery to better understand the market and its users.

Through AccelerateRU, Rowan's startup accelerator, Nicholas gained access to mentors, coaches, workshops, industry experts, entrepreneurial programming, and Rowan's broader venture ecosystem.

AccelerateRU at Rowan University →

The value of those programs was not simply participation.

They gave PCN repeated opportunities to expose the idea to people who could question it, challenge it, and help improve it.

That process helped turn an early concept into an operating company.

PCN was also tested through university, regional, national, and global entrepreneurship competitions.

Nicholas Denzer and Pharma Connect Navigator earned:

• Second place at the Collegiate Entrepreneurs' Organization Global Pitch Competition
• Second place at the EO GSEA Philadelphia competition
• Second place at Rowan University's New Venture Competition
• First place and the Audience Choice Award at the statewide UPitchNJ competition
• A Top 7 finish in the Global Scaling Challenge
• Selection as one of 30 semifinalist ventures from across the United States for the America250 / Meet the Drapers America's Startup competition

PCN did not advance into the final 10 of the America250 competition.

The value of these competitions went beyond awards.

Each one required Nicholas to explain and defend the company in front of judges, entrepreneurs, investors, university leaders, and people outside the pharmaceutical industry.

The company repeatedly had to answer fundamental questions:

Is the problem real?

Who experiences it?

Why is the existing process insufficient?

What makes PCN different from a directory?

Does the business have a viable path forward?

Can a specialized problem in pharmaceutical outsourcing be communicated clearly enough that someone outside the industry understands why it matters?

That repeated scrutiny helped refine the company.

External links:

Rowan University: UPitchNJ

Rowan University: New Venture Competition

Rowan Entrepreneurship: CEO Global Pitch Competition

Rowan Entrepreneurship: Global Scaling Challenge

America250: America's Startup

Pharma Connect Navigator is a portfolio company of the Rowan Innovation Venture Fund, managed by Garden State Venture Partners.

Garden State Venture Partners publicly lists PCN within the fund's portfolio and describes the company as focused on algorithm-based CDMO matching for biotechnology and pharmaceutical manufacturing partners.

Garden State Venture Partners, Rowan Innovation Venture Fund Portfolio →

Rowan University separately announced Garden State Venture Partners' appointment to manage the next phase of the Rowan Innovation Venture Fund.

Rowan University, Garden State Venture Partners and the Rowan Innovation Venture Fund →

For PCN, the backing represents more than access to capital.

It connects the company with experienced investors, operators, advisors, and a broader entrepreneurial ecosystem as PCN continues developing into a commercial life-sciences technology company.

PCN does not disclose the investment amount publicly on this page.

Nicholas Denzer is the founder and CEO of Pharma Connect Navigator.

His route into biotechnology began differently from that of a scientist, pharmaceutical executive, or career CMC professional.

His experience as a patient created a personal connection to medical innovation.

Entrepreneurship gave him a way to search for problems worth solving.

Customer discovery led him to the inefficiencies surrounding CDMO search and manufacturing-partner selection.

Industry professionals helped him understand the complexity behind those decisions.

PCN became the company through which those experiences came together.

Nicholas's role is not to replace the experts who have spent their careers in pharmaceutical development and manufacturing.

It is to build technology and infrastructure that can help those experts and the teams they support work more efficiently.

Several principles guide the way Pharma Connect Navigator is being built.

Project fit matters more than universal rankings.

A CDMO should be evaluated in the context of the specific manufacturing program.

Facilities matter.

Company-level information may not accurately describe the capabilities of every manufacturing site.

Data provenance matters.

Regulatory records, official CDMO information, manufacturer-entered data, and unknown information should not be treated as identical forms of evidence.

Regulatory information requires context.

Inspection observations should inform diligence rather than automatically determine manufacturer suitability.

Unknown information should remain visible.

Missing information should not quietly become an assumed fact.

Software should support professional judgment, not replace it.

Technology can improve sourcing and comparison, but experienced CMC, technical, quality, regulatory, and manufacturing professionals remain essential to final decision-making.

And ultimately:

The goal is not a Match %.

The goal is a better-qualified conversation between a sponsor and a manufacturing partner that may actually fit the program.

Pharma Connect Navigator's mission is to reduce unnecessary friction between promising medical innovation and the manufacturing infrastructure required to move it forward.

A biotechnology company can have extraordinary science and still face years of development work before that science can reach a patient.

Manufacturing is one critical part of that journey.

PCN cannot determine whether a therapy will be safe or effective.

It cannot run a sponsor's CMC organization.

It cannot replace scientists, quality professionals, regulatory experts, CMC consultants, or experienced manufacturing teams.

What PCN can do is work on a narrower problem:

Help teams identify potentially relevant manufacturing partners, investigate them with better context, and reach better-qualified conversations with less unnecessary work.

When biotechnology development can take years, avoidable delays matter.

When emerging companies operate with limited capital and bandwidth, wasted effort matters.

And when the ultimate objective is a medical innovation intended to improve someone's life, reducing unnecessary friction in the development process is worth pursuing.

That is why Pharma Connect Navigator exists.

Information about Pharma Connect Navigator's development, recognition, programs, and venture backing can also be found through independent public sources.

Rowan University: UPitchNJ

Coverage of Nicholas Denzer and Pharma Connect Navigator winning first place and the Audience Choice Award at the statewide UPitchNJ competition, along with references to earlier competition results.

Rowan University: New Venture Competition

Coverage of PCN's participation in the 2026 New Venture Competition.

Rowan Entrepreneurship: CEO Global Pitch Competition

Coverage of Nicholas Denzer's second-place finish at the global competition.

Rowan Entrepreneurship: Global Scaling Challenge

Coverage of the Rowan team's Top 7 finish.

NSF I-Corps at Rowan University

Information about Rowan's participation in the NSF I-Corps Northeast Region Hub and its customer-discovery programming.

AccelerateRU

Information about Rowan University's startup accelerator.

Garden State Venture Partners

Public portfolio listing for Pharma Connect Navigator through the Rowan Innovation Venture Fund.

America250 / America's Startup

Information about the national startup competition and PCN's semifinalist participation.

Pharma Connect Navigator is supported by experienced professionals spanning CMC, pharmaceutical development, manufacturing operations, product strategy, venture capital, entrepreneurship, and executive leadership.

Meet the Team & Advisors →